Acute Promyelocytic Leukemia
📧 Sign up to get email alerts when something new happens for Acute Promyelocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... [Phase 1]
Phase I trial of pexidartinib (TURALIO) in children and young adults with refractory leukemias and solid tumors including NF1-associated ple…
-
EMA approval · 2026-04-21EMA Authorised: Arsenic trioxide medac (arsenic trioxide) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Arsenic trioxide medac for the treatment of acute promyelocytic leukemia.
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 1]
An MD Anderson trial is evaluating PET/MRI, 18F-FDG PET/CT, and whole-body MRI to detect extramedullary myeloid leukemia in patients with ne…
-
CLINICAL_TRIALS research · 2026-04-16Clinical Trial Update: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia [Phase 3]
This update outlines the ongoing pivotal open-label Phase 3 trial of QTX-2101 in adults with acute promyelocytic leukemia. The study is curr…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL). [Phase 3]
This clinical trial update indicates a Phase 3 study evaluating Realgar-Indigo Naturalis Formula (RIF) combined with all-trans retinoic acid…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-13EMA Authorised: Arsenic trioxide Accord (arsenic trioxide) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Arsenic trioxide Accord for the treatment of acute promyelocytic leukemia.
-
EMA approval · 2026-01-30EMA Authorised: Trisenox (arsenic trioxide) — Teva B.V.
The European Medicines Agency has authorised Trisenox (arsenic trioxide) by Teva B.V. for use in acute promyelocytic leukemia.
-
FDA approval · 2026-01-30FDA Approved: ARSENIC TRIOXIDE — Supplemental Application (Eugia US LLC)
The FDA approved a supplemental application for arsenic trioxide from Eugia US LLC under an ANDA. This action updates regulatory details for…
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301) [Phase 3]
Phase 3 trial LATITUDE/SDKARS-301 is evaluating whether oral arsenic trioxide is similar to intravenous arsenic trioxide in pharmacokinetics…
-
CLINICAL_TRIALS research · 2025-12-17Clinical Trial Update: Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia [Phase 2]
This is a Phase 2 trial evaluating tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin in newly diagnosed acute promyelocyt…
-
CLINICAL_TRIALS research · 2025-12-11Clinical Trial Update: French Registry of First-line Treatment of Acute Promyelocytic Leukemia
French registry study documenting first-line treatment of acute promyelocytic leukemia; sponsored by Groupe Francophone des Myelodysplasies,…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia [Phase 1]
Phase 1 trial evaluated the pharmacokinetics of an oral arsenic trioxide solution under fasting and fed conditions and compared it to intrav…
-
CLINICAL_TRIALS trial_result · 2025-10-31Clinical Trial Update: AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment [NA]
A completed clinical trial evaluating the LEAP AI-assisted evaluation platform versus clinician-only assessment in acute promyelocytic leuke…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia [NA]
Clinical trial evaluating the combination of venetoclax with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) for hyperleukocytic a…
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Frontline Oral Arsenic Trioxide for APL [Phase 2]
A Phase 2 trial evaluating frontline oral arsenic trioxide for acute promyelocytic leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-30Clinical Trial Update: Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating oral arsenic in combination with all-trans retinoic acid (ATRA) for newly diagnosed acute promyelocytic le…
-
EMA withdrawal · 2025-05-06EMA Withdrawn: Arsenic trioxide Mylan (arsenic trioxide) — Mylan Ireland Limited
The EMA has withdrawn the arsenic trioxide product Arsenic trioxide Mylan (Mylan Ireland Limited) used for acute promyelocytic leukemia.
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia [NA]
Clinical trial results have been posted evaluating a simplified patient-care strategy to reduce early death in acute promyelocytic leukemia …
-
FDA approval · 2025-03-03FDA Approved: TRETINOIN — Original Application (Encube Ethicals, Inc.)
The FDA approved Encube Ethicals’ original application for tretinoin, granting a generic version of the dermatology retinoid. This marks a f…
-
CLINICAL_TRIALS trial_result · 2025-02-26Clinical Trial Update: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [Phase 3]
Phase 3 study NCT02688140 in newly diagnosed, high-risk Acute Promyelocytic Leukemia has completed. The entry notes the trial status as COMP…
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating chidamide in combination with venetoclax for retinoic acid- and arsenic-resistant acute promyelocytic leuk…
-
FDA approval · 2025-01-29FDA Approved: TRETINOIN — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves Glenmark's supplemental application for tretinoin (all-trans retinoic acid), updating the product's regulatory status per the s…
-
FDA approval · 2025-01-13FDA Approved: TRETINOIN — Original Application (Aurobindo Pharma Limited)
FDA approved an Original Application for tretinoin from Aurobindo Pharma Limited, making a generic version of tretinoin available. This is a…
-
CLINICAL_TRIALS research · 2024-08-09Clinical Trial Update: Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial is evaluating venetoclax to prevent differentiation syndrome in patients with acute promyelocytic leukemia,…
-
FDA approval · 2024-07-08FDA Approved: ARSENIC TRIOXIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for arsenic trioxide from Zydus Pharmaceuticals USA Inc. under ANDA206228.